Harrow Quarterly Cash Flow Statement
NASDAQ: HROWHealth CareBiotechnology: Pharmaceutical PreparationsUSD
29.36-1.16 (-3.80%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Harrow free cash flow
In the quarter ended Jun 30, 2026, Harrow generated -$9.8 million of operating cash flow and spent $491,000 on capital expenditures. That left free cash flow of -$10.2 million, a free-cash-flow margin of -14.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Harrow cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -17.27M | -27.60M | 6.63M | 1.02M | 5.00M | -17.78M | 6.78M | -4.22M | -6.47M | -13.56M | -9.15M | -4.39M |
| Net Income growth (YoY) | -445.75% | — | -2.23% | — | — | — | — | — | — | — | -967.11% | — |
| Depreciation & Amortization | 460.00K | 455.00K | 330.00K | 326.00K | 347.00K | 312.00K | 321.00K | 351.00K | 301.00K | 296.00K | 435.00K | 405.00K |
| Stock-Based Compensation | 3.79M | 3.84M | 3.80M | 3.27M | 875.00K | 4.56M | 4.79M | 4.38M | 4.27M | 4.17M | 4.17M | 4.48M |
| Change in Working Capital | -5.10M | 9.94M | -12.54M | -4.38M | -12.31M | 41.63M | -37.44M | -3.15M | -7.95M | -128.00K | 8.56M | -6.47M |
| Operating Cash Flow | -9.76M | -8.99M | 8.41M | 16.59M | -803.00K | 19.67M | -17.78M | 2.95M | -2.75M | -4.63M | 8.70M | -1.21M |
| Capital Expenditures | -491.00K | -194.00K | -341.00K | -210.00K | -166.00K | -170.00K | -555.00K | -604.00K | -344.00K | -92.00K | -194.00K | -520.00K |
| Investing Cash Flow | -534.00K | -18.20M | -4.73M | -225.00K | -293.00K | -212.00K | -37.56M | -597.00K | 5.10M | -110.00K | -203.00K | -20.13M |
| Debt Issued | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Debt Repaid | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Financing Cash Flow | -466.00K | 48.91M | -5.04M | 4.96M | -12.67M | 23.00K | 29.98M | -721.00K | 73.00K | -809.00K | -18.00K | 64.19M |
| Net Change in Cash | -10.76M | 21.72M | -1.36M | 21.33M | -13.76M | 19.48M | -25.35M | 1.63M | 2.43M | -5.55M | 8.47M | 42.86M |
| Free Cash Flow | -10.25M | -9.19M | 8.07M | 16.38M | -969.00K | 19.50M | -18.33M | 2.35M | -3.09M | -4.72M | 8.50M | -1.73M |
This table shows 12 quarterly periods of Harrow's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow HROW's reporting calendar. What is a cash flow statement?